Arno Therapeutics, Inc. announced that the FDA has granted its request for orphan drug designation for AR-42 for the treatment of meningioma and schwannoma of the central nervous system. Meningioma and schwannoma are benign tumors that can present in different locations within the brain and the spinal cord and may cause substantial morbidity for those affected individuals.

AR-42 is an orally available, broad-spectrum deacetylation inhibitor of both histone and non-histone proteins that play an important role in the regulation of gene expression, cell growth, and survival.

For more information, call (862) 703-7170 or visit www.arnothera.com.